Department of Economics, Bogazici University, Bebek, Istanbul, Turkiye.
Graduate School of Public Health, City University of New York, Ann Arbor, MI, USA.
Expert Opin Pharmacother. 2024 Aug;25(11):1565-1573. doi: 10.1080/14656566.2024.2391524. Epub 2024 Aug 12.
Obesity has been established as a significant risk factor for osteoarthritis. Anti-obesity medications (AOMs) have demonstrated efficacy in weight management. However, potential impact on osteoarthritis risk remains uncertain.
This retrospective cohort study used Kythera data from NOV2022 to JULY2024. Patients with obesity using AOMs were identified through diagnosis and prescription claims for tirzepatide, semaglutide, or liraglutide between 1NOV2023 and 31JAN2024, with a 6-month follow-up to assess OA risk. OA risk, analyzed using Cox regression and propensity score matching, controlled for comorbidities and sociodemographic factors.
There were 39,394 patients living with obesity using AOM (23,933 semaglutide 12,854 tirzepatide, 2,607 liraglutide) and 72,405 without AOM use. The adjusted osteoarthritis risk was 27% % lower in AOM users than in non-users (hazard ratio (HR) = 073, 95% CI (0.67-0.79), < 0.01). Among AOMs, tirzepatide was associated with a significantly lower osteoarthritis (OA) risk compared to semaglutide (HR = 0.57, 95% CI: 0.50-0.65, < 0.0001). Liraglutide was linked to a significantly higher OA risk vs tirzepatide (HR = 1.63, 95% CI: 1.23-2.15, = 0.0007).
AOM use was associated with a significantly lower risk of OA and may be an effective obesity management intervention.
肥胖已被确定为骨关节炎的一个重要危险因素。抗肥胖药物（AOM）在体重管理方面已被证明有效。然而，其对骨关节炎风险的潜在影响仍不确定。
这是一项回顾性队列研究，使用了 Kythera 公司 2022 年 11 月至 2024 年 7 月的数据。通过诊断和处方记录，确定在 2023 年 11 月 1 日至 2024 年 1 月 31 日期间使用 tirzepatide、semaglutide 或 liraglutide 的肥胖患者，并在 6 个月时评估 OA 风险。使用 Cox 回归和倾向评分匹配分析 OA 风险，控制合并症和社会人口因素。
共纳入 39394 名使用 AOM 的肥胖患者（semaglutide 12854 名，tirzepatide 23933 名，liraglutide 2607 名）和 72405 名未使用 AOM 的肥胖患者。与未使用者相比，AOM 使用者的骨关节炎风险降低了 27%（调整后危险比（HR）=0.73，95%置信区间（CI）：0.67-0.79， < 0.01）。在 AOM 中，与 semaglutide 相比，tirzepatide 与骨关节炎（OA）风险显著降低相关（HR=0.57，95%CI：0.50-0.65， < 0.0001）。与 tirzepatide 相比，liraglutide 与 OA 风险显著升高相关（HR=1.63，95%CI：1.23-2.15， = 0.0007）。
AOM 使用与 OA 风险显著降低相关，可能是一种有效的肥胖管理干预措施。
